Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

Regulatory Peptides

Volumn 114, Issue 2-3, 2003, Pages 115-121

  Vilsbøll, Tina ^a,b   Krarup, Thure ^a   Madsbad, Sten ^a   Holst, Jens J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GIP receptors; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Incretin hormones; Insulin secretion

Indexed keywords

AMIDE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HORMONE; INCRETIN; POLYPEPTIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG INHIBITION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HUMAN EXPERIMENT; INFUSION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MEAL; PHYSIOLOGY; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 0038121744     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(03)00111-3     Document Type: Article

References (27)

1. Kolligs F., Fehmann H.C., Goke R., Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 44:1995;16-19.
2. Tseng C.C., Kieffer T.J., Jarboe L.A., Usdin T.B., Wolfe M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 98:1996;2440-2445.
3. Wang Z., Wang R.M., Owji A.A., Smith D.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 is a physiological incretin in rat. J. Clin. Invest. 95:1995;417-421.
4. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Eaton R.P., Ebert R.et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63:1986;492-498.
5. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 2:1987;1300-1304.
6. Edwards C.M.B., Todd J.F., Mahmoudi M., Wang Z.L., Wang R.M., Ghatei M.A.et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - studies with the antagonist exendin 9-39. Diabetes. 48:1999;86-93.
7. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L.et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:1996;1254-1258.
8. Meier J.J., Hucking K., Holst J.J., Deacon C.F., Schmiegel W.H., Nauck M.A. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 50:2001;2497-2504.
9. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 76:1993;912-917.
10. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y.et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14843-14847.
11. Jia X., Brown J.C., Ma P., Pederson R.A., Mcintosh C.H.S. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin-secretion. Am. J. Physiol.: Endocrinol. Metab. 31:1995;E645-E651.
12. Toft-Nielsen M., Madsbad S., Holst J.J. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia. 41:1998;1180-1186.
13. Nauck M., Schmidt W.E., Ebert R., Strietzel J., Cantor P., Hoffmann G.et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J. Clin. Endocrinol. Metab. 69:1989;654-662.
14. Deacon C.F., Nauck M.A., Meier J., Hucking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85:2000;3575-3581.
15. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 43:1994;535-539.
16. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 50:2001;609-613.
17. Gutniak M.K., Larsson H., Heiber S.J., Juneskans O.T., Holst J.J., Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care. 19:1996;843-848.
18. Krarup T., Madsbad S., Moody A.J., Regeur L., Faber O.K., Holst J.J.et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J. Clin. Endocrinol. Metab. 56:1983;1306-1312.
19. Krarup T., Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul. Pept. 9:1984;35-46.
20. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:1991;415-423.
21. Mccullough A.J., Miller L.J., Service F.J., Go V.L.W. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric-inhibitory polypeptide. J. Clin. Endocrinol. Metab. 56:1983;234-241.
22. Pederson R.A., Brown J.C. Insulinotropic action of gastric inhibitory polypeptide in perfused isolated rat pancreas. Endocrinology. 99:1976;780-785.
23. Fehmann H.C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16:1995;390-410.
24. Hvidberg A., Nielsen M.T., Hilsted J., Orskov C., Holst J.J. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism. 43:1994;104-108.
25. Orskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:1996;665-670.
26. Muller W.A., Faloona G.R., Aguilar-Parada E., Unger R.H. Abnormal alpha-cell function in diabetes - response to carbohydrate and protein ingestion. N. Engl. J. Med. 283:1970;109-116.
27. Ohneda A., Aguilar-Parada E., Eisentraut A.M., Unger R.H. Control of pancreatic glucagon secretion by glucose. Diabetes. 18:1969;1-10.